Marine Protein Hydrolysate as Dietary Supplement in Elderly Part I

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-27

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the potential effect of a marine protein hydrolysate (MPH) supplement before a meal on postprandial glucose tolerance in healthy subjects, to achieve more knowledge on this presumed beneficial, blood glucose lowering effect

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of a Marine Protein Hydrolysate in Healthy Adults

NCT05149079

Healthy Diet

COMPLETED NA

Effect Study of Marine Protein Hydrolysates to Prevent Loss of Muscle Mass and Physical Function in Frail Elderly

NCT02890290

Sarcopenia

COMPLETED NA

Effect of Oral Nutritional Supplements to Older Patients Discharged With a Rehabilitation Plan

NCT05556876

Nutritional Risk Rehabilitation Oral Nutritional Supplements

ENROLLING_BY_INVITATION NA

A Study on the Effects on Glucose Regulation, Inflammation and Serum Lipids After Fish Protein Supplementation in Elderly (GRIPE)

NCT03529344

Muscle Weakness Muscle Loss Blood Sugar; High +2 more

COMPLETED NA

Impact of Predialytic Oral Protein on Nutritional Status and Quality of Life in HD Patients

NCT05952570

Hemodialysis Complication

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To further investigate the effects of MPH in a single dose of 20 mg/kg of body weight on postprandial blood glucose, insulin and GLP-1 (as markers of glucose metabolism) in healthy, active middle-aged to elderly subjects - age 40-65 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

A double-blind crossover trial, including two different study days, with 4-7 days wash-out (WO) period in between. The intervention implemented 20 mg of MPH per kg body weight (test material) or control (casein).

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

supplementary Marine protein hydrolysate

20 mg powder per kg body weight of Marine protein hydrolysate (MPH)

Group Type EXPERIMENTAL

Marine protein hydrolysate (mph)

Intervention Type DIETARY_SUPPLEMENT

Marine (Cod) protein hydrolysate

control

20 mg powder per kg body weight of casein/maltodextrin

Group Type PLACEBO_COMPARATOR

Control

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin/Casein

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Marine protein hydrolysate (mph)

Marine (Cod) protein hydrolysate

Intervention Type DIETARY_SUPPLEMENT

Control

Maltodextrin/Casein

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent
* Body mass index (BMI) 20-30

Exclusion Criteria

* Suspected allergies against fish or shellfish
* Low or unstable blood pressure
* Diabetes mellitus, treated pharmacological
* Chronic diseases or therapies that is likely to interfere with the evaluation of study results
* Acute infections (may be reconsidered for inclusion at a later time)
* Allergic to milk, confirmed diagnose
* Pregnancy
* Women who are breast-feeding infants
* Inability or unwillingness to comply with the requirements of study procedures

Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes